Halozyme Therapeutics (NASDAQ:HALO) Director Sells $294,720.00 in Stock

Key Points

• Director Bernadette Connaughton of Halozyme Therapeutics sold 4,000 shares at an average price of $73.68, totaling $294,720, reducing her position by 7.85%.
• Halozyme reported a 40.8% year-over-year revenue increase, with $325.72 million for the quarter and earnings per share exceeding estimates at $1.54.
• The stock has a 52-week range of $42.01 to $74.44, and it currently has a consensus rating of "Hold" with a target price of $67.11.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) Director Bernadette Connaughton sold 4,000 shares of the company's stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $73.68, for a total value of $294,720.00. Following the transaction, the director directly owned 46,952 shares in the company, valued at $3,459,423.36. This trade represents a 7.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Halozyme Therapeutics Stock Performance

NASDAQ HALO traded up $0.19 on Tuesday, hitting $73.34. 2,684,821 shares of the stock were exchanged, compared to its average volume of 2,173,515. Halozyme Therapeutics, Inc. has a 52 week low of $42.01 and a 52 week high of $74.44. The company has a market capitalization of $8.58 billion, a PE ratio of 16.78, a P/E/G ratio of 0.42 and a beta of 1.19. The business's fifty day moving average is $61.48 and its 200 day moving average is $59.48. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, topping the consensus estimate of $1.23 by $0.31. The company had revenue of $325.72 million for the quarter, compared to analysts' expectations of $282.66 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The business's revenue for the quarter was up 40.8% on a year-over-year basis. During the same period last year, the firm earned $0.91 earnings per share. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of institutional investors have recently modified their holdings of HALO. Heck Capital Advisors LLC purchased a new stake in Halozyme Therapeutics in the 4th quarter worth approximately $29,000. Wealth Preservation Advisors LLC bought a new stake in shares of Halozyme Therapeutics in the 1st quarter worth about $32,000. Newbridge Financial Services Group Inc. bought a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at about $32,000. SVB Wealth LLC acquired a new position in Halozyme Therapeutics during the 1st quarter valued at about $33,000. Finally, Bessemer Group Inc. raised its holdings in shares of Halozyme Therapeutics by 62.9% in the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 207 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on HALO shares. Leerink Partnrs lowered Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Tuesday, May 13th. Leerink Partners cut Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 target price on the stock. in a research note on Tuesday, May 13th. JPMorgan Chase & Co. lifted their target price on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the stock a "neutral" rating in a research report on Thursday, August 7th. Morgan Stanley increased their price objective on shares of Halozyme Therapeutics from $75.00 to $80.00 and gave the stock an "overweight" rating in a research note on Monday, August 18th. Finally, Wells Fargo & Company increased their price objective on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the company an "equal weight" rating in a research report on Wednesday, May 7th. Four equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of "Hold" and a consensus price target of $67.11.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.